Sjögren syndrome
ICD-10 M35.0 · ICD-11 4A43.2

Sjögren Syndrome with Active Arthritis When Immunosuppressive Therapy Has Not Met Its Target

This protocol applies to patients with Sjögren syndrome who have active articular inflammation and active systemic disease, and whose prior immunosuppressive therapy did not achieve the required disease-activity reduction. It describes the next escalation step.

Clinical Scenario
Sjögren syndrome with arthritis — objective inflammation of one or more joints — and active systemic disease (clinESSDAI score ≥1). Arthritis is confirmed by physical examination findings (heat, redness, and swelling of the affected joint), with ultrasound used to support the assessment when findings are uncertain. The ESSDAI score further classifies arthritis severity by the number of joints involved.
Previous Treatment: Target Not Reached
A prior line of immunosuppressive agents as glucocorticoid-sparing therapy — which may include leflunomide, methotrexate, azathioprine, mycophenolate, or cyclophosphamide, managed along rheumatoid arthritis principles — did not achieve the required reduction of ≥3 points in the global ESSDAI score. This protocol is the next clinical step after that failure.
Next-Step Approach
The evidence-based protocol for this situation involves rituximab. The full regimen — including administration details and scheduling — is available in the complete structured protocol.

The defined treatment target remains a reduction of ≥3 points in the global ESSDAI score, consistent with the task force recommendation for measuring therapeutic response in systemic Sjögren syndrome.

Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.1136/annrheumdis-2019-216114
Arthritis is clinically diagnosed on the basis of objective inflammation of >=1 joints (heat, redness and swelling in the physical examination of the affected joint) supported by ultrasound studies when in doubt, and the ESSDAI score classifies the severity of arthritis according to the number of joints involved (moderate <5 joints, high >5).
The use of rituximab may be considered in patients with severe, refractory systemic disease.
With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of >=3 points in the global ESSDAI score.
View source ↗